Clinical Trial

Tear Interleukin Biomarkers After Glaucoma Treatment

Study acronym: TIGT
Recruiting
View on ClinicalTrials.gov →
Summary
This prospective study aims to evaluate inflammatory biomarkers in tear fluid in patients with glaucoma undergoing micropulse transscleral cyclophotocoagulation (MP-CPC), continuous-wave cyclophotocoagulation (CPC), and antiglaucoma surgeries. The study will assess the concentrations of pro- and anti-inflammatory interleukins in tear samples collected before treatment, 5-7 days after the procedure, and 1 month postoperatively. Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in interleukin levels and IOP reduction will be analyzed. Additionally, the study aims to compare inflammatory response patterns among the MP-CPC, CPC, and surgical treatment groups and to identify interleukin profiles associated with a clinically significant hypotensive effect.
Trial Details
NCT Number NCT07592988
Lead Sponsor Kazakh Eye Research Institute
Conditions Glaucoma
Enrollment 24 participants
Start Date 2026-05-18
Primary Completion 2026-08-18 (estimated)
Study Completion 2026-08-18 (estimated)
Updated on ClinicalTrials.gov 2026-05-18